Inhibition of Jak1 and Jak2 by topically applied ruxolitinib or momelotinib successfully decreased inflammation in a hapten-induced hypersensitivity model as well as in TSLP-induced dermatitis in mice together with the down-regulation of mRNA expression of IL-4, IL-5, IFNγ, and TSLP in the skin (95, 96). This evidence concerns the gene JAK1 and skin disorder.